- | Sernova Corp
Towards a ‘Functional Cure’ for Diabetes with Dr. Philip Toleikis, CEO, Sernova Corp – Xtalks Life Science Podcast Ep. 70
In this episode, the editorial team spoke with the President and CEO of regenerative medicine biotech Sernova Corp Dr. Philip Toleikis to learn more about how the company is developing a ‘functional cure’ for diabetes.
- | SOTIO
SOTIO Biotech starts solid tumor trial
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors.
- | Cerevance
New approaches in CNS diseases, Brad Margus, Co-founder and Executive Chairman, Cerevance
Brad Margus is co-founder and Executive Chairman of Cerevance, a drug discovery company advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.
- | SOTIO
Treatment With SOT101 and Pembrolizumab Commences in Phase 2 AURELIO-04 Study
SOT101 is an interleukin (IL)-15 superagonist that had demonstrated preclinical efficacy in various tumor models. Specifically, the agent prolonged survival and improved tumor regression in in vivo models. The agent also demonstrated a favorable toxicity profile preclinically.
- | PepGen
Oligonucleotide Opportunities in DMD with PepGen’s James McArthur, Ph.D.
The Business of Biotech caught up with Dr. McArthur at PepGen’s Cambridge headquarters to learn more.
- | IMV Inc.
Platform for Meaningful Delivery of Cancer Vaccines for Multiple Tumor Types with Andrew Hall IMV
Andrew Hall is the CEO of IMV Inc, which has developed a platform based on a lipid-in-oil technology that encapsulates the therapeutic. When injected subcutaneously, the drug remains in a specific location to reinvigorate the immune system to overcome the tumor surveillance that allows cancer to grow.
- | Portage Biotech
Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline
Portage Biotech is helmed by CEO Ian Walters and CSO Robert Kramer, and backed by three biotech entrepreneurs — UK investor Jim Mellon, ex-Biohaven board member Declan Doogan and early Medivation backer Greg Bailey — who have whipped up a whole slate of different ventures aimed at drug development.
- | Omega Therapeutics
PharmaShots Interview: Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022
OTX-2002 is our lead Omega Epigenomic Controller™ (OEC) candidate designed to downregulate the expression of c-Myc (MYC), a key gene involved in cellular growth commonly overexpressed in cancer cells. OECs are programmable mRNA medicines that encode a two-part protein: a DNA binding domain that specifies the target location on the DNA, which we call EpiZips™, and an effector domain that makes precise and durable epigenetic marks to alter gene expression. OECs are translated into proteins by the cell’s ribosomal machinery, then travel to the nucleus to lay epigenetic marks at the programmed specific genomic address.
